News | February 03, 2014

Researcher Finds Significant Cardiac Treatment Imbalance Nationally

February 3, 2014 — Percutaneous coronary intervention (PCI) centers are unequal relative to population and heart attack prevalence across the United States, according to a study in the Journal of the American Heart Association. A multi-center team led by James Langabeer II, Ph.D., The University of Texas Health Science Center at Houston, conducted the study
 
Langabeer and co-lead author Timothy Henry, M.D., Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, found that people who live in urban areas have access to more PCI centers than necessary. Those who live in some rural areas are unable to access a PCI center within 60 minutes, the recommended time to receive treatment after the onset of heart attack symptoms.
 
Researchers examined the distribution of PCI centers in each state and compared that to population density and heart attack prevalence. The number of PCI centers has grown 21 percent nationwide in the last eight years, with 39 percent of all hospitals having interventional cardiology capabilities. While PCI centers continue to grow, heart attacks are decreasing. Langabeer’s discovery unveils an unequal geographic distribution of PCI capacity for treating heart attack patients.
 
Some western states, such as Nevada, had higher than median disease prevalence rates, yet have only an average number of PCI centers for its population. Locations in the south central and north central region, such as Alabama and Montana, had significantly higher relative PCI facilities compared to some of the states with even higher disease rates.
 
“There is a growing trend nationally for hospitals to all become PCI capable, for a variety of reasons. As long as the capacity is aligned with the need, this is positive. However, in this research, we found significant disparity geographically when we normalized capacity by population density” Langabeer said. “These imbalances are creating problems on a national scale.”
 
The study is called "Growth in Percutaneous Coronary Intervention Capacity Relative to Population and Disease Prevalence." Co-authors are from the American Heart Association, Boston University School of Medicine, Duke University Medical Center, The Christ Hospital Heart and Vascular Center and UT Southwestern Medical Center.
 
For more information: www.ahajournals.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init